The stakes are larger than many clinicians appreciate. Although breast cancer remains predominantly a disease of older women, incidence among American women aged 20 to 49 has been climbing, with 2024 analyses examining incidence by race, stage and hormone receptor status documenting a rise in early-onset cases. Every year, tens of thousands of women in the prime of their reproductive lives hear the words “you have breast cancer.” Their tumors are often more aggressive — triple-negative and HER2-positive subtypes are overrepresented in younger patients — and their treatment regimens correspondingly intense. Yet these are also the women most likely to face a decades-long survivorship horizon, for whom questions about ovarian function, fertility and childbearing will shape quality of life for half a century. The review’s authors frame fertility as an integral pillar of survivorship care rather than an optional consultation to be deferred until treatment is finished and the ovarian reserve is already depleted.

The biological problem begins with arithmetic. A woman is born with a finite bank of primordial follicles — roughly one to two million at birth, dwindling to a few hundred thousand by puberty — and, unlike men, who regenerate sperm continuously, she can never manufacture more. Chemotherapy attacks this non-renewable reserve directly. The worst offender in breast cancer regimens is cyclophosphamide, an alkylating agent that damages the small cells supporting immature follicles. Recent work indicates the destruction follows two parallel routes: apoptosis of the follicles themselves, and a “burnout” phenomenon in which dormant follicles are prematurely activated and then die without ever reaching maturity. The result is a dose-dependent collapse of the ovarian reserve, traceable in blood through falling levels of anti-Müllerian hormone within months of treatment. A 2025 systematic review and meta-analysis confirmed that chemotherapy exerts a high impact on ovarian reserve among reproductive-age survivors, with the magnitude shaped largely by age, dose and regimen.

The clinical signature of this damage is often chemotherapy-induced amenorrhea, the shutdown of menstrual cycles that may prove temporary or permanent depending on how old the patient is and how toxic her regimen. Paradoxically, amenorrhea has also been linked to better survival in hormone-sensitive tumors, turning a reproductive catastrophe into a prognostic marker. But gonadotoxicity does not end with cytotoxic drugs. Curative therapy routinely includes five to ten years of endocrine treatment with tamoxifen or an aromatase inhibitor — drugs that do not destroy follicles but push childbearing into a future when the reserve will have declined regardless. Meanwhile, the newest generation of targeted agents, including CDK4/6 inhibitors, anti-HER2 antibodies, antibody–drug conjugates and immune checkpoint inhibitors, has accumulated only fragmentary fertility data. Emerging studies suggest some of these agents may affect the ovary, while others appear relatively gentle — trastuzumab has even been reported to attenuate chemotherapy-induced ovarian toxicity — but the evidence remains thin.

Against this backdrop, the review identifies oocyte and embryo cryopreservation as the first-line methods of fertility preservation, both of which require compressing a full cycle of ovarian stimulation into the narrow window between diagnosis and chemotherapy. Modern protocols have answered the two long-standing objections. Vitrification — ultra-rapid freezing that prevents destructive ice crystals from forming inside the cell — has largely solved the fragility of the human oocyte, with systematic review data showing clear advantages over older slow-freezing techniques. And stimulation no longer demands the estrogen surges once feared to fuel tumor growth: pairing gonadotropins with aromatase inhibitors such as letrozole keeps estradiol concentrations near baseline, and safety analyses of women with early breast cancer have found no signal of worse recurrence after the procedure. A prospective nationwide Swedish study showed that GnRH-antagonist stimulation protocols can be executed safely in this population, typically consuming two to three weeks that most early-stage treatment plans can accommodate.

For patients who cannot afford even that delay, or who have not yet reached puberty, ovarian tissue cryopreservation offers an alternative that is experimental in name only: thin strips of ovarian cortex containing thousands of primordial follicles are removed laparoscopically, frozen, and transplanted back once the patient is cured. Sixty live births had been reported worldwide by 2015, and subsequent network analyses — including a single German program that performed ninety-five orthotopic transplantations in seventy-four women — confirm meaningful pregnancy and delivery rates, alongside an unresolved debate about the theoretical risk of reintroducing malignant cells. A pharmacological option has also matured: monthly injections of a gonadotropin-releasing hormone agonist during chemotherapy, which suppress the pituitary–ovarian axis and appear to shield resting follicles from being recruited into a toxic environment. The POEMS trial of goserelin, published in the New England Journal of Medicine, and a later individual-patient-data meta-analysis both demonstrated significant reductions in ovarian failure and higher pregnancy rates, although the strategy is viewed as an adjunct to, not a substitute for, gamete preservation.

The question that once overshadowed all others — is pregnancy after breast cancer safe? — has now been answered about as definitively as medical science allows. A 2021 systematic review and meta-analysis found no evidence that pregnancy increases the risk of recurrence or death after breast cancer, including among women with estrogen-receptor-positive disease, the subtype long presumed most vulnerable. The landmark POSITIVE trial went further, testing whether women with endocrine-responsive cancer could safely pause tamoxifen or an aromatase inhibitor after eighteen to thirty months of therapy in order to try to conceive. Its initial results, published in the New England Journal of Medicine in 2023, showed no significant increase in short-term breast cancer events among the 516 participants who interrupted treatment, and updated analyses reported in 2026 continue to support the approach. Guidelines now list pregnancy after stage 0 to 3 breast cancer as considered safe, and even breastfeeding may be possible after surgery, depending on the extent of treatment.

Yet evidence this strong is not reaching patients evenly. The review catalogs a persistent implementation gap: guidelines from ASCO, ESHRE and the American Society for Reproductive Medicine all call for a fertility discussion before gonadotoxic therapy begins, but mixed-methods studies of oncology practice show the conversation happens inconsistently, and audits of breast cancer clinical trials reveal that ovarian toxicity is rarely captured as an endpoint at all. An American Society of Clinical Oncology research statement published in The Lancet Oncology in 2023 called for standardized measurement of ovarian function in trials, noting that without deliberate assessment, the gonadotoxicity of new agents simply goes undetected. The psychological stakes are concrete: pretreatment fertility counseling and preservation have been shown to improve quality of life in young women with cancer, while decision regret over options that were never offered can shadow survivors for years.

Access is the second fault line. Fertility preservation can cost tens of thousands of dollars, insurance coverage in the United States remains a patchwork of state mandates — although political momentum has recently expanded such mandates to twenty-one states plus the District of Columbia — and geospatial analyses published in JAMA Oncology in 2023 identified stark disparities in proximity to oncofertility services, with some patients living hours from the nearest program. Studies of young women with cancer have repeatedly documented lower use of fertility preservation among Black and Hispanic patients and those of lower socioeconomic status, and reviews of NCI-designated cancer center websites found that fertility information is often incomplete or difficult to locate. The consequence, the authors write, is that the chance to bank gametes before chemotherapy all too often tracks with zip code, income and insurance status rather than with medical suitability.

The remedy, the researchers argue, is structural: early, structured fertility counseling built into multidisciplinary cancer care, with reproductive endocrinologists embedded in tumor boards rather than consulted belatedly. Single-institution programs that added a fertility specialist to breast tumor boards report sharp increases in counseling and preservation rates, and dedicated oncofertility programs have measurably expanded access to reproductive procedures. Emerging strategies — in vitro maturation of immature oocytes, artificial ovary constructs, and cyclophosphamide-free chemotherapy regimens validated in a randomized phase 3 trial — point toward a future in which preservation becomes faster, cheaper and less invasive. For a growing population of long-term survivors, the review reframes fertility not as a luxury but as a core component of survivorship medicine, on par with cardiac monitoring and bone health. The evidence now shows that surviving breast cancer and building a family are compatible goals; the remaining task is ensuring that every reproductive-age patient hears that message while her options are still open.

The conundrum faced by women suffering from infertility due to borderline ovarian tumors is multi-layered. On one hand, these tumors, classified as low malignant potential, often present a significant risk for recurrence, especially when the biological response to ovarian stimulation is taken into account. On the other hand, women desiring to conceive may be caught in a challenging situation where treatment options for infertility are not only limited but must also be analyzed through the lens of oncological safety. The new findings presented in this study provide a critical understanding of how different COS protocols influence the likelihood of tumor recurrence.

The investigators meticulously analyzed various COS protocols that are routinely employed in IVF treatments. Each regimen was designed with distinct hormonal and pharmacological profiles intended to optimize ovarian response while safeguarding the health of the patient. This nuanced approach underscores the necessity to tailor treatment plans that not only address infertility but do so with a vigilant eye on the patient’s oncological background. The study differentiates between standard COS protocols and those modified for patients with a history of borderline tumors, aiming to strike a balance between efficacy and safety.

Essential to this research was the utilization of a robust patient cohort, drawn from multiple institutions. This diversity in sample size and demographic representation contributes to the credibility and generalizability of the findings. The study involved a thorough examination of health records, tumor markers, and IVF cycle outcomes, all meticulously documented to offer comprehensive insights into the long-term implications of varied COS regimens. By conducting such an extensive analysis, the researchers were able to identify critical trends that could dictate treatment decisions for similar cases.

One particularly noteworthy finding of the study is that certain COS regimens were associated with heightened risks of tumor recurrence—an alarming revelation that necessitates a reevaluation of standard practices in IVF protocols for affected women. The implications of this discovery extend beyond individual patient care; they prompt a broader discussion about the need for oncological considerations to be integrated into fertility treatment plans. This underscores the importance of interdisciplinary collaboration between reproductive specialists and oncologists in optimizing patient outcomes.

Another intriguing aspect of the study is its approach to understanding the hormonal milieu associated with IVF cycles in patients with borderline tumors. The hormonal environment—characterized by fluctuations in estrogen and progesterone during COS—plays a crucial role in not just stimulating ovarian function but also in influencing tumor biology. This vital connection between reproductive hormones and cancer progression highlights the need for a more explicit focus on endocrinological factors in future research.

The implications of these findings extend to informing future clinical guidelines and patient consultations. Through a combination of data-driven insights and direct patient feedback, healthcare providers can engage in more informed discussions about the risks associated with various treatment modalities. Moreover, this partnership between clinician and patient can lead to shared decision-making that takes into account both fertility desires and oncological risks.

As this study paves the way for further exploration into the realms of reproductive health and cancer risk, it signifies a larger movement within the medical community towards precision medicine—customizing treatment plans to fit individual needs and circumstances effectively. By prioritizing patient safety without sacrificing the possibility of conception, the hope is to develop comprehensive care pathways that empower women facing these dual challenges.

It is also crucial to acknowledge the ongoing need for continued research. The landscape of fertility treatments and cancer management is ever-evolving, necessitating perpetual advancements in both knowledge and practice. As more data emerge, physicians will be better equipped to refine their approaches, ultimately leading to improved patient outcomes.

In summary, the study led by Liang and colleagues offers vital insights that could revolutionize the way healthcare professionals manage fertility treatments among women with a history of borderline ovarian tumors. By meticulously evaluating the effects of different COS regimens on tumor recurrence and IVF success rates, the research underscores the importance of safety in fertility treatments. With the right balance of hormonal stimulation and oncological vigilance, the prospects for women facing the dual challenges of fertility and cancer may improve, enabling a more hopeful future.

With advancements in medical research, it is essential that practitioners stay informed about emerging evidence that might influence therapeutic strategies. The intersection of oncology and reproductive health is not only a burgeoning field of study but also a vital aspect of comprehensive patient care that prioritizes both safety and the potential for successful conception.

As we move forward, it will be exciting to witness the ways in which these findings reshape clinical practice and contribute to the ongoing dialogue surrounding treatment for women grappling with infertility and malignancies. It is a reminder of the intricate connections between different aspects of health and the importance of a holistic approach to medical care.

In conclusion, this study acts as a clarion call for researchers and clinicians alike to work collaboratively to innovate and improve standards of care for women who find themselves navigating the complex pathways of infertility and cancer risk.

Subject of Research: The study investigates the risk of tumor recurrence following different COS regimens in infertile women with borderline ovarian tumors and their impact on IVF outcomes.

Article Title: Tumor recurrence risk following different COS regimens in infertile women with borderline ovarian tumors: impact on IVF outcomes.

Article References: Liang, L., Li, Y., Zhen, XM. et al. Tumor recurrence risk following different COS regimens in infertile women with borderline ovarian tumors: impact on IVF outcomes. J Ovarian Res 18, 253 (2025). https://doi.org/10.1186/s13048-025-01819-8

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13048-025-01819-8

Keywords: IVF, tumor recurrence, borderline ovarian tumors, COS regimens, reproductive health, cancer, fertility treatment, hormonal stimulation, patient safety.